BiotechTube
SynaptixBio

SynaptixBio

Oxford, United Kingdom· Est.
synaptixbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.7M

Overview

SynaptixBio is a private, pre-clinical stage biotech developing antisense oligonucleotide (ASO) therapies for rare, fatal leukodystrophies caused by TUBB4A gene mutations. The company holds key regulatory designations from the FDA, including Rare Paediatric Drug and Orphan Drug Designations for its lead programs targeting H-ABC and Isolated Hypomyelination. With a seasoned leadership team, SynaptixBio is advancing candidate selection for clinical trials and positioning itself as the sole potential therapeutic provider for a significant unmet medical need affecting thousands of children globally.

Rare Neurological DiseasesLeukodystrophies

Technology Platform

Antisense oligonucleotide (ASO) gene silencing platform targeting mutated mRNA to prevent production of toxic proteins.

Funding History

2
Total raised:$1.7M
Grant$500K
Seed$1.2M

Opportunities

As the only company licensed to commercialize a treatment for H-ABC, SynaptixBio has a first-mover advantage in an area of catastrophic unmet need with no approved therapies.
Successful development could command premium pricing and benefit from orphan drug exclusivity, while the ASO platform offers potential expansion into other related neurodegenerative disorders.

Risk Factors

The company faces high scientific risk in demonstrating safety and efficacy of its ASO therapy in the complex brain environment, and significant funding/execution risk as a pre-revenue, early-stage biotech.
Commercialization challenges include conducting robust trials in an ultra-rare pediatric population and securing reimbursement for a high-cost therapy.

Competitive Landscape

SynaptixBio claims to be the only company licensed to commercialize a treatment for H-ABC, suggesting no direct competitors for its specific TUBB4A-targeted ASO. However, it operates in the broader, competitive fields of gene therapy, RNA therapeutics, and leukodystrophy research, where other modalities (e.g., gene replacement) may be in development for related disorders.

More companies in RNA Therapeutics (non-mRNA) →More companies in United Kingdom →